北京若生智能科技有限公司
Drug Database
AM

amphotericin B (Ampholip)

✓ Approved

Bharat Serums and Vaccines Limited · 小分子 · 小分子

什么是 amphotericin B？

amphotericin B 是一种小分子，由Bharat Serums and Vaccines Limited研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Ampholip
公司Bharat Serums and Vaccines Limited
药物类别小分子
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Bharat Serums and Vaccines Limited

治疗适应症

amphotericin B 针对 3 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Cardiac disordersEndocardial disease✓ Approved
Infections and infestationsCandida infection✓ Approved
Infections and infestationsAspergillus infection✓ Approved

相关研究文献

PubMedJAC-antimicrobial resistance2026-09-10

Performance of the Sensititre YeastOne assay compared with EUCAST E.Def 9.4 against Fusarium clinical isolates: focus on voriconazole and amphotericin B.

Chen Pao-Yu PY, Wu Un-In UI, Liu Wang-Da WD, Huang Yu-Tsung YT et al.

Despite the global emergence of Fusarium infections, data validating commercial antifungal susceptibility testing against these moulds remain scarce. We evaluated the performance and optimal reading time of the Sensititre YeastOne (SYO) assay against Fusarium clinical isolates compared with the EUCAST reference method. This two-centre study (2011-2023) analysed 123 Fusarium isolates identified via two-step molecular sequencing. In vitro susceptibilities to voriconazole and amphotericin B were evaluated using SYO (24 h and 48 h readouts) versus the EUCAST E.Def 9.4 broth microdilution reference method (48 h readout). Essential agreement (EA) was defined as a ±2 log2 dilution difference; >90% was acceptable. Fusarium solani species complex (FSSC) dominated the cohort (85.3%), predominantly F. keratoplasticum and F. pseudensiforme. EUCAST testing revealed high MIC50/MIC90 values of voriconazole (>16/>16 mg/L) and amphotericin B (2/16 mg/L). While 65% (80/123) of isolates displayed positivity by SYO at 24 h, median spectrophotometric growth was significantly greater at 48 h than at 24 h [0.37 (IQR 0.315-0.403) versus 0.18 (0.151-0.206)]. At 48 h, EA approached acceptability for voriconazole (92.7%) and amphotericin B (89.4%). Voriconazole categorical agreement (CA) among FSSC was 88.6% and reached 96.9% for F. pseudensiforme. For amphotericin B, SYO MICs clustered around 4-8 mg/L, yielding 100% very major error for F. keratoplasticum and F. pseudensiforme but 100% CA for F. falciforme, F. petroliphilum and non-FSSC. Voriconazole and amphotericin B susceptibility determined by SYO cannot universally replace reference methods due to failure to detect non-WT to amphotericin B for prevalent species within FSSC. However, alongside accurate species-level molecular identification, SYO provides actionable susceptibility data for validated species-antifungal combinations.

PMID 42718997
阅读全文 →
PubMedCase reports in critical care2026-09-10

Early Disseminated Cryptococcosis Following Orthotopic Heart Transplantation Requiring VA-ECMO: A Case Report.

Petrich Vanessa V, Deschenes Lucas L

Disseminated cryptococcosis is a rare but serious opportunistic infection following solid organ transplantation and rarely occurs within the first month of transplantation. We report a case of disseminated Cryptococcus neoformans infection occurring 14 days after orthotopic heart transplantation which required mechanical circulatory support with venoarterial extracorporeal membrane oxygenation (VA-ECMO). Management was complicated by alterations in antifungal pharmacokinetics and the inability to perform serial lumbar punctures while anticoagulated. Antifungal therapy with nonliposomal amphotericin B, flucytosine, and fluconazole was administered. A combination of optic nerve sheath diameter measurements, CT scans, and evaluation for papilledema was used as temporizing, noninvasive surrogates for intracranial pressure monitoring until lumbar punctures could be safely performed. The patient was successfully decannulated, weaned from mechanical support, and discharged from the intensive care unit.

PMID 42718971
阅读全文 →
PubMedmSphere2026-09-10

Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistant Cryptococcus neoformans and Candida albicans.

Ayala Magali M, Jakamartana Alifia A, Costa Rodrigo Mamede Dos Santos RMDS, Cheung Eric Cheuk-Kiu EC-K et al.

Systemic fungal infections cause an estimated 3.8 million deaths annually, approximately 10% of which are caused by drug-resistant infections. With only five classes of antifungal drugs, treatment options are limited. Here, we explore synergistic drug combinations-when the efficacy of two drugs combined is greater than expected based on the sum of each individual drug's efficacy-to improve treatment of drug-resistant Cryptococcus neoformans and Candida albicans. Chlorpromazine acts synergistically with both amphotericin B and fluconazole against multiple fungal species, including azole-resistant C. neoformans and C. albicans. We then performed a genome-wide knockout mutant screen and found that ESCRT pathway mutants are resistant to chlorpromazine, while knockout mutants of genes involved in fatty acid biosynthesis are sensitive. Based on these data, we investigated sterol and fatty acid composition in chlorpromazine-treated cells and found only minor increases in sterol precursors, but a substantial increase in lipid droplet size and decreased lipid droplet numbers. This lipid droplet formation potentially sequesters lipid bioavailability and response to membrane stress. Together, these data suggest that chlorpromazine and its analogs are potentially promising treatments for systemic fungal infections that act via lipid homeostasis and stress response. Fungal infections are a large and expensive health burden with high mortality rates. People with compromised immune systems from cancer, solid organ transplant, HIV infection, and other conditions are particularly affected. Systemic fungal infections are difficult to treat because there are few available drugs and treatment periods last months or years. Long treatment times increase the risk of treatment failure and can contribute to the rise of resistance. We identified an additional class of drugs, chlorpromazine and other phenothiazine drugs, that amplify the activity of existing antifungal drugs amphotericin B (AmB) and fluconazole (FLZ). AmB and FLZ act by targeting ergosterol, the fungal equivalent of cholesterol, which is required for a functional plasma membrane. Chlorpromazine increases the formation of lipid drops, which sequester lipids such as ergosterol. When chlorpromazine is combined with AmB, the fungal cell cannot respond to the plasma membrane damage caused by AmB, inhibiting the fungal cells. This work identifies new target processes and drugs that could treat deadly fungal infections.

PMID 42720352
阅读全文 →
PubMedFrontiers in medicine2026-09-10

A case report of Emergomyces orientalis infection in the lung of HIV infected in patient and literature review.

Luo Lifeng L, Guo Ying Y, Nie Zunzhen Z

This study reports a rare case of pulmonary Emergomyces orientalis infection with clinical characteristics, diagnostic approaches and therapeutic regimens of this rare fungal infection, aiming to provide evidence for clinical diagnosis and management. We retrospectively analyzed the patient's clinical symptoms, imaging manifestations, laboratory examinations including metagenomic next-generation sequencing (mNGS), diagnostic and therapeutic procedures, as well as prognosis. Related published literature was searched, reviewed and summarized. The patient presented with a 3-day cough and expectoration. Conventional pathogen examinations showed the patient is infected with the HIV virus and definite diagnosis of Emergomyces orientalis infection was finally confirmed by mNGS of lung biopsy specimens. He received liposomal amphotericin B combined with symptomatic supportive therapy. Clinical symptoms were alleviated and pulmonary lesions were absorbed after treatment. Pulmonary Emergomyces orientalis infection is uncommon and prone to missed diagnosis and misdiagnosis with high mortality. Routine pathogen culture yields a low positive rate. mNGS serves as a critical tool for early and accurate diagnosis. Individualized antifungal treatment, strict drug interaction assessment and therapeutic monitoring are essential to optimize clinical prognosis.

PMID 42719226
阅读全文 →
PubMedScientific reports2026-09-10

Molecular divergence and genomic composition of B chromosomes in the fish Cyphocharax modestus (Characiformes, Curimatidae).

Dos Santos Natalia N, Sassi Francisco de Menezes Cavalcante FMC, Dos Santos Rodrigo Zeni RZ, Goes Caio Augusto Gomes CAG et al.

B chromosomes are supernumerary elements that evolve from standard A chromosomes and are primarily composed of repetitive DNAs, yet their origin, diversification, and molecular composition remain poorly understood in most vertebrates. We investigated two allopatric populations of Cyphocharax modestus (Curimatidae) combining classical cytogenetics, comparative genomic hybridization (CGH), and comparative satellitomics to characterize the repetitive DNA landscape of its B chromosomes. While both populations exhibited a conserved karyotype of 2n=54 biarmed chromosomes, five individuals from the Batalha River (BR) carried supernumerary chromosomes, comprising two distinct variants: a C-positive B1 and an C-negative B2. Comparative satellitome analysis between 3B-carrying and B-lacking individuals identified 116 satellite DNAs (CmoSatDNAs), with the 3B library showing higher abundances of specific sequences. Fluorescence in situ hybridization (FISH) revealed that both B variants share two centromeric satellites (CmoSat01-192 and CmoSat02-108) with the A complement, while CmoSat58-47 was exclusively to B2. Minimum spanning tree analysis of CmoSat58-47 revealed B-exclusive haplotypes alongside haplotypes shared with B-lacking individuals, suggesting a recent origin for these chromosomes. CGH experiments further confirm the sequence sharing between the A and B chromosomes, supporting an intraspecific origin, and revealing substantial genomic differentiation among B variants.

PMID 42717220
阅读全文 →
PubMedFood science & nutrition2026-09-10

Mechanistic Study of Schisandrin B in Alleviating Anxiety-Like Behaviors in Rats via Enhancement of Hippocampal Synaptic Plasticity and Restoration of the Intestinal Barrier.

Tian Jia-Yu JY, Wang Rui-Ze RZ, Wang Hong-Kun HK, Ye Xiao-Nan XN et al.

This study focused on examining the anxiolytic effects of Schisandrin B (SchB) in rats exhibiting anxiety-like behaviors and investigating the mechanisms involved. Behavioral assessments were conducted using the elevated plus-maze test and the open field test. The results showed that Schisandrin B at a dose of 10 mg/kg significantly alleviated anxiety-like behaviors in rats, with an efficacy comparable to that of the positive control drug diazepam. Mechanistic studies indicate that, at the central level, Schisandrin B effectively maintains the homeostasis of the glutamatergic system in the hippocampus and the HPA axis. Specifically, Schisandrin B downregulates the stress-induced overexpression of ionotropic glutamate receptor subunits at both the mRNA and protein levels, including NMDAR subtypes (GluN1A, GluN2A, and GluN2B) and AMPAR subtypes (GluA1 and GluA2), thereby restoring the glutamate/γ-aminobutyric acid (Glu/GABA) ratio to physiological levels. In addition, Schisandrin B suppresses the hyperactivation of the HPA axis by reducing the secretion of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and corticosterone (CORT). Meanwhile, it ameliorates neuronal and synaptic ultrastructural damage in the hippocampus and upregulates the expression of synaptic plasticity-related proteins, SYP and PSD-95, thereby improving synaptic transmission and function. At the peripheral intestinal level, Schisandrin B alleviated colon shortening in anxiety-model rats and reduced fecal pH, thereby improving intestinal environmental homeostasis. Schisandrin B also promoted the upregulation of tight junction proteins (ZO-1, Occludin, and Claudin-1) in the colonic tissues, contributing to the restoration of colonic mucosal integrity, attenuation of inflammatory infiltration, and reinforcement of intestinal barrier function. Collectively, Schisandrin B exerts systemic anxiolytic effects by centrally regulating hippocampal glutamatergic neurotransmission, HPA axis activity, and synaptic plasticity, while simultaneously repairing peripheral intestinal barrier dysfunction. These results indicate the potential of Schisandrin B as a therapeutic candidate for anxiety disorders.

PMID 42718869
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多amphotericin B